1. Насонов Е.Л. 50 лет применения метотрексата в ревматологии. РМЖ. 2000; 9: 372–6.
2. Агаджанян Г.Н., Балабанова Р.М. Сравнительная эффективность иммунодепрессивных препаратов при ревматоидном артрите. Клин. мед. 1988; 8: 58–62.
3. Furst DE, Breedveld FC, Kalden J et al. Update consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2006; 65 (Suppl. 3): 2–15.
4. Насонов Е.Л. Метотрексат.Перспективы применения в ревматологии. М., 2005; 16–28.
5. Niedel J, Sova L, Schroers B. Effect of methotrexate on normal articular cartilage in vitro and in vivo. Ann Rheum Dis 1998; 57: 414–21.
6. Cronstein NB, Levine RE, Philips MR et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immun 1992; 148: 2201–6.
7. Johnston CA, Russell AS, Kovithaavongs T et al. Measures of immunologic and inflammatory responses in vitro in rheumatoid arthritis patients treated with methotrexate. J Rheum 1986; 13: 294–6.
8. Hoekstra M, Haagsma C, Neef C et al. Bioavailability of higher dose methotrexate cjmparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheum 2004; 31: 645–8.
9. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficasy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthr Rheum 2006; 54: 1087–95.
10. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recomendations for the use of methotrexate in rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086–93.
11. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094–9.
12. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheum 1997; 36: 86–90.
13. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1232–4.
14. Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheum 2006; 35: 102–6.
15. Braun J, Kaestner P, Flaxenberg P at al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthrit Rheum 2008; 58: 73–81.
16. Salliot C, van der Heijde D. Long term safety of methotrexate monotherapy in rheumatoid arthritis patients: a systematic literature research. Ann Rheum Dis 2009; 68: 1100–4.
17. Kremer JM, Furst DE, Weinblatt ME et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumat 1996; 23: 459–61.
18. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7.
19. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflamatory musculoskeletal disoders. Rheumatology(Oxford) 2006; 45: 1370–5.
20. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthrit Rheum 2002; 46: 2294–300.
21. Mariette X, Cazals-Hatem D, Warszawski J et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909–15.
22. Hoshida Y, Xu JX, Fujita S et al. Lympfoproliferative disoders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007; 34: 322–31.
23. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthrit Rheum 2004; 50: 1740–51.
24. Ros S, Iuanola X, Condom E et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheum 2002; 31: 330–6.
25. Kent PD, Luthra HS, Michet C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in rheumatoid arthritis patients. J Rheumat 2004; 31: 1727–31.
26. Kremer JM, Kaye GI, Kaye NW et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow up over long treatment intervals and correlation with clinical and laboratory variables. Arthrit Rheum 1995; 38: 1194–203.
27. Fathi NH, Mitros F, Hoffman J et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy,or toxicity during a 3,5 year double blind study in rheumatoid arthritis. J Rheumatol 2002; 29: 2092–8.
28. Hornung N, Ellingsen T, Stengaard-Pedersen K et al. Folate, homocystein and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumat 2004; 31: 2374–81.
29. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthrit Rheum 2001; 44: 1515–24.
30. Katchamart W, Ortiz Z, Shea B et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (an update systematic review and metaanalysis). Arthrit Rheum 2008; 58 (Suppl.): 473.
31. Morgan SL, Baggott JE, Vaugh WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthrit Rheum 1990; 9–18.
32. Morgan SL, Baggott JE, Vaugh WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Inern Med 1994; 121: 833–41.
33. Griffith SM, Fisher J, Clarke S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) 2000; 39: 1102–9.
34. Combe B, Landewe R, Lukas C et al. EULAR recomendations for the management of early arthritis: report of a task force of the European Standing Commitee for international Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34–45.
35. Saag KG, Teng GG, Patkar NM et al. ACR 2008 recommendations for the use of nonbiologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr Rheum 2008; 59: 762–84.
36. Genovese M, Keystone EC, Tesser JRP et al. High dose oral methotrexate in early rheumatoid arthritis is needed for maximum efficacy. Arthr Rheum 2000; 43 (Suppl.): 382 (abstr.)
37. Kay J, Westhovens R. Methotrexate: the gold standart without standartisation. Ann Rheum Dis 2009; 68: 1081–2.
38. Katchamart W, Trudeau J, Phumethum V et al. Efficacy and toxicity of methotrexate monotherapy versus methotrexate combination therapy with non-biological DMARD in rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2009; 68: 1105–12.
39. Choy EHS, Smith C, Dore CJ et al. A metaanalysis of the efficacy and toxicity of combining DMARD in rheumatoid arthritis based on patients withdrawal. Rheumatology (Oxford) 2005; 44: 1414–21.
40. O’Dell JR, Left R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroqine, methotrexate and sulfasalasine or combination of the three medication: results of two-year, randomized, double-blind, placebo-controlled trial. Arthr Rheumat 2002; 46: 1164–70.
41. Lipsky PE, van der Heijde D, St.Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
42. St.Clair EW, van der Heijde D, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004; 50: 3432–43.
43. Smolen JS, van der Heijde D, St.Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from ASPIRE trial. Arthr Rheum 2006; 3: 702–10.
44. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthr Rheum 2005; 52: 3381–90.
45. van der Kooij S, le Cessie S, Goekoop-Ruiterman YP et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1153–59.
46. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody for treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial. Arthr Rheum 2003; 48: 35–45.
47. van der Heijde D, Burmester G, Melo-Gomes J et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis 2009; 68: 1113–8.
48. Murata K,Yasuda T, Ito H et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 2006; 26: 14–9.
49. Ostensen M, Hartmann H, Salvessen L. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumat 2000; 27: 1872–5.